

Association between Blood N-3 Fatty Acid Levels and Risk for COVID-19 in the UK biobank

William S. Harris, PhD^{1,2}; Nathan L. Tintle, PhD^{1,3}, Swaminathan Perinkulam Sathyanarayanan, MD² and Jason Westra, MS¹

¹Fatty Acid Research Institute, Sioux Falls, SD, USA

²Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA.

³Department of Population Health Nursing Science, College of Nursing, University of Illinois – Chicago, Chicago, IL, USA

Sources of Support: This analysis was supported in part by the William H. Donner Foundation which played no role in any aspect of this investigation.

Conflict of Interest: WSH holds stock in OmegaQuant Analytics, LLC, a laboratory that offers blood fatty acid testing (including the Omega-3 Index) for researchers, clinicians and consumers. NLT, SPS and JW have nothing to disclose.

Corresponding Author: William S. Harris, PhD. 5009 W. 12th St, Ste 5b, Sioux Falls, SD, 57106. (913) 302-9433; wsh@faresinst.com

Running Title: N-3 Fatty Acid Levels Predict COVID-19 Outcomes

Abbreviations: CI, confidence interval; eO3I, estimated Omega-3 Index (erythrocyte EPA+DHA%); HR, hazard ratio.

William Harris is a member of the Journal's Editorial Board

1 **Abstract**

2 Background: The role of nutritional status and risk for contracting and/or suffering adverse outcomes
3 from SARS-CoV-2 infection is unclear. Preliminary studies suggest that higher n-3 PUFA intakes may be
4 protective. Objectives: The purpose of this study was to compare risk for three COVID-19 outcomes
5 (testing positive for SARS-CoV-2, hospitalization, and death) as a function of baseline plasma DHA levels.
6 Methods: DHA levels (% of total fatty acids) were measured by nuclear magnetic resonance. The three
7 outcomes and relevant covariates were available for 110,584 subjects (hospitalization and death) and
8 for 26,595 ever-tested subjects (positive for SARS-CoV-2) in the UK Biobank prospective cohort study.
9 Outcome data between January 1, 2020 and March 23, 2021 were included. Omega-3 Index (red blood
10 cell EPA+DHA%) values across DHA% quintiles were estimated. Multi-variable Cox-proportional hazards
11 models were constructed and linear (per 1-SD) relations with risk for each outcome were computed as
12 hazard ratios (HRs). Results: In the fully adjusted models, comparing the fifth to the first DHA% quintiles,
13 the HR for testing positive (95% CI) was 0.79 (0.71, 0.89; $p < 0.001$), for being hospitalized was 0.74 (0.58,
14 0.94; $P < 0.05$), and for dying with COVID-19 was 1.04 (0.69, 1.57; NS). On a per 1-SD increase in DHA%
15 basis, the HRs were: for testing positive, 0.92 (0.89, 0.96; $p < 0.001$); for hospitalization, 0.89 (0.83, 0.97;
16 $p < 0.01$); and for death, 0.95 (0.83, 1.09). Estimated Omega-3 Index values across DHA quintiles ranged
17 from 3.5% (quintile 1) to 8% (quintile 5). Conclusions: These findings suggest that nutritional strategies
18 to increase circulating n-3 PUFA levels, such as increased consumption of oily fish and/or use of n-3 fatty
19 acid supplements, may reduce risk for adverse COVID-19 outcomes.

20

21 **Key Words: EPA, DHA, Omega-3 Index, COVID-19, SARS-CoV-2, fish oil, epidemiology, observational,**
22 **biomarker**

23

24

25 **Introduction**

26 The COVID-19 pandemic has arguably been the most disruptive worldwide event since World War II. Its
27 impact was felt not only in the health sector (morbidity and mortality), but also in the economic, social
28 and political realms. A tremendous amount of research has been conducted on the causes of and
29 treatments for the infection, including efforts to discover the factors that affect susceptibility to the
30 disease. In addition to demographic and physiologic characteristics (e.g., obesity, age, underlying health
31 conditions, socio-economic status, etc.), nutritional considerations have been explored. Nutrients such
32 as zinc, vitamins C and D, as well as dietary bioactives (e.g., probiotics) have been suggested as possible
33 protective agents against SARS-CoV-2 infection and/or COVID-19 sequelae(1). In addition to these, the
34 long-chain n-3 fatty acids of marine origin – EPA and DHA - have also been proposed to be protective
35 against COVID-19(2-5). DHA and EPA are the main precursors for inflammation resolving mediators,
36 including maresins, resolvins and protectins (6). These mediators downregulate the production of
37 cytokines and also improve macrophage-mediated removal of inflammatory debris, microbes and
38 promote apoptosis of neutrophils(2). Accordingly, higher levels of EPA and DHA in the tissues could
39 reduce the severity of the inflammatory response to SARS-CoV-2 infection. Small (<100 patients) studies
40 have reported that higher red blood cell levels of EPA+DHA (i.e., the Omega-3 Index, O3I(7)) at
41 admission were associated with lower risk for adverse COVID-19 outcomes(8-10), and pilot intervention
42 studies have reported possible benefits from n-3 supplementation(11-13). The availability of plasma
43 DHA levels in a subset of individuals in the UK Biobank cohort(14) affords the opportunity to explore the
44 relationships between n-3 biostatus and risk for COVID-19 outcomes. Two prior studies on this topic
45 have been published. Julkunen et al.(15) and Sun et al.(16) both recently reported that higher DHA
46 levels, among several other biomarkers, were associated with lower risk for infection with or
47 hospitalization with COVID-19. In addition, reported use of fish oil supplements was recently linked with
48 lower risk for COVID-19 in the UK cohort(17). The purpose of the present study was to expand upon the

49 work of these investigators by 1) examining the n-3 relations with additional COVID-19 outcomes (i.e.,
50 death), 2) performing more granular analyses (i.e., quintiles), 3) exploring the effects of several
51 covariates on these relationships, and 4) translating n-3 biostatus into the O3I, a more commonly used
52 measure of n-3 status.

53

54 **Methods**

55 *Participants:* UK Biobank is a prospective, population-based cohort of approximately 500,000 individuals
56 recruited between 2007 and 2010 at assessment centers across England, Wales and Scotland. Baseline
57 data derived from questionnaires, biological samples and physical measurements were collected on all
58 participating individuals, with longitudinal monitoring occurring via a mix of in-person and Electronic
59 Medical Record data(14, 18). The participants completed a touchscreen questionnaire, which collected
60 information on socio-demographic characteristics, diet, and lifestyle factors. Anthropometric
61 measurements were taken using standardized procedures. The touchscreen questionnaire and other
62 resources are shown on the UK Biobank website (<http://www.ukbiobank.ac.uk/resources/>). UK Biobank
63 has ethical approval (Ref. 11/NW/0382) from the North West Multi-centre Research Ethics Committee
64 as a Research Tissue Bank. This approval means that researchers do not require separate ethical
65 clearance and can operate under the Tissue Bank approval. All participants gave electronic signed
66 informed consent. The UK Biobank study was conducted according to the guidelines laid down in the
67 Declaration of Helsinki. The UK Biobank protocol is available online ([http://www.ukbiobank.ac.uk/wp-](http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf)
68 [content/uploads/2011/11/UK-Biobank-Protocol.pdf](http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf)).

69

70 A total of 117,946 individuals from the UKbiobank cohort had blood fatty acid data (**Supplementary**
71 **Flow Diagram**). We first, dropped people who died before January 1, 2020 (i.e., before the pandemic
72 began), leaving a sample of N=111,240 individuals. After dropping a small number of individuals with
73 missing covariates (listed below under Statistical methods) our final analysis dataset consisted of
74 N=110,584.

75

76 *Exposure:* The primary exposure was plasma DHA (expressed as a percent of total plasma fatty acids)
77 obtained from blood samples collected at time of enrollment using by nuclear magnetic resonance
78 (Nightingale Health Plc, Helsinki, Finland(19)). In order to estimate the O3I associated with these DHA
79 levels, we used an equation described by Schuchardt et al.,(20) which found a correlation between the
80 observed and estimated O3I (eO3I) of 0.83.

81

82 *Outcomes:* We examined three primary endpoints: (1) death from COVID, (2) hospitalization with
83 confirmed SARS-CoV-2 infection, and (3) having tested positive for SARS-CoV-2. Data were available on
84 these three outcomes through March 23, 2021 including the outcome itself (yes/no) and the date for
85 which the outcome was recorded. Any individuals recorded as having died and/or been hospitalized
86 with COVID were imputed as having tested positive for COVID if not already noted as such in the dataset
87 (N=174, 4% of the total). Because of inconsistencies in the reporting of testing data across regions of
88 the UK (e.g., testing data were not available for Wales), and to provide a more precise outcome
89 measure, the analysis sample for the 'tested positive' outcome, consisted of only individuals for whom a
90 test result was available (e.g., ever tested; N=26,597). Links to the UK Biobank outcomes, exposures and
91 covariates used here are given in **Supplementary Table 6**.

92

93 *Statistical Methods:* Cox-proportional hazards models were used to predict all three outcomes. For each
94 outcome, four separate models were run predicting the outcome using DHA% while using different sets
95 of covariates with prior evidence of association with confirmed infection with SARS-CoV-2(21). Model 1
96 unadjusted; Model 2 adjusted for age at start of pandemic, sex, and race (self-identified); Model 3

97 included Model 2 covariates + waist circumference; and Model 4 included Model 3 covariates +
98 Townsend Deprivation Index (a measure of relative socio-economic status), time since enrollment,
99 smoking status, education, self-reported health, blood pressure medications, slow walking pace, fresh
100 fruit, dried fruit, salad/raw vegetables, cooked vegetables and grain fiber (from cereals and breads (22)).
101 For models with sets of covariates which substantially attenuated hazard ratios (particularly Models 2 vs
102 3), the relative contribution of each individual variable to the explained variation was evaluated by a
103 drop-one analyses. The effect of dropping each individual covariate illuminates the relative impact of
104 each on the model concordances. Other covariates identified in prior studies(21) for test positivity
105 included cystatin-C, HbA1c, forced expiratory volume, and HDL cholesterol. However, these variables
106 were missing for $\approx 17\%$ of subjects, thus, we only included them in a sensitivity analysis (Model 5 =
107 Model 4 covariates + these four variables). As in prior studies, we focused primarily on modeling the
108 relationships between DHA% and COVID outcomes with quintiles and continuous linear relationships. In
109 secondary analyses we further investigated potential non-linearities using cubic splines. Cubic splines
110 were compared to linear models using nested ANOVA to test for significant model improvement. All
111 analyses were conducted in R version 4.1.2. and used a 0.05 statistical significance threshold.

112

113 **Results**

114 Descriptions of the analytic cohorts are presented in **Table 1**. Among the 110,584 people included in this
115 study, the average age at the beginning of the pandemic was about 68 yrs, the vast majority were White
116 and a little less than half were males. The average plasma DHA value was 2%, and the eO3I was 5.6%.
117 Less than 1% of the full cohort were hospitalized with COVID, and about 20% of those hospitalized died
118 from it. Among the 26,597 people in the dataset who ever got tested for SARS-CoV-2 infection, about
119 15% tested positive at some point between January 1, 2020 and March 23, 2021. In those who got
120 tested, plasma DHA% was similar to that of the whole cohort. When divided into quintiles, the plasma
121 DHA% ranged from $<1.49\%$ in quintile 1 to $>2.50\%$ in quintile 5 (**Tables 2-4**). The median eO3I values
122 corresponding to each plasma DHA% quintile ranged from 3.54% to 7.96% in quintiles 1 and 5,
123 respectively (**Figure 1**).

124

125 There was a strong, inverse and dose-related relationship between plasma DHA% and risk for having a
126 positive SARS-CoV-2 test (**Figure 1A**) which was partially attenuated with each level of multivariable
127 adjustment (**Table 2**). Nevertheless, in the fully adjusted model, individuals in quintile 5 were 21% less
128 likely to test positive than those in quintile 1 ($p < 0.001$), and the risk for a positive test was 8% lower for
129 each 1-SD increase in plasma DHA% ($p < 0.001$).

130

131 As regards hospitalization with COVID, again there was again a significant, inverse association with the
132 plasma DHA % which was partially attenuated with increasing adjustment (**Figure 1B**). In the fully
133 adjusted model (**Table 3**), individuals in quintile 5 were at 26% lower risk for hospitalization than those
134 in quintile 1 ($P < 0.05$), and risk was 11% lower per 1-SD higher in DHA% ($p < 0.001$).

135

136 Finally, for death from COVID, relations with plasma DHA% were more complex (**Figure 1C, Table 4**). In
137 all models, risk for death was significantly lower in quintile 4 vs quintile 1 ($p < 0.05$), but in quintile 5, the
138 risk reduction was partially attenuated and not significant in three of the four models (the exception
139 being model 2 where risk was 39% lower, $p < 0.05$). In the unadjusted model and model 2, risk for death
140 was 17% and 22%, respectively, lower ($p < 0.05$) per 1-SD increase in DHA%. However, in the fully
141 adjusted model, it was attenuated to non-significance (Table 4). Also in this model, the difference
142 between risk for death in quintiles 4 and 5 was significant ($p = 0.04$).

143

144 As mentioned for all three outcomes, there was some attenuation of the relationship between DHA%
145 and risk with adjustment for covariates. Most of the attenuation in risk, particular for hospitalization and
146 death, was seen in model 3, which added waist circumference as a covariate in addition to age, sex and
147 race [from model 2)]. It was therefore of interest to examine each of these four covariates to see the
148 extent to which each was responsible the observed attenuation in relationship. This was done by
149 computing the concordance between DHA% and each of the three outcomes, and then systematically
150 removing each of the variables from the model and calculating the resultant drop in concordance. The
151 results of this exercise are shown in **Table 5**. Regardless of the outcome, the removal of sex and then
152 race from the covariate list had little effect on the concordance. Age and waist circumference were the
153 more important covariates. For testing positive, the inclusion of age had the greatest impact on the
154 observed association with DHA%, decreasing the concordance by 45%. Comparatively, the removal of
155 waist circumference reduced the concordance by only 3%. For hospitalization, waist circumference was
156 the more influential, reducing concordance by 19% compared to 10% for age. For death, age was again
157 the major factor followed by waist circumference, reducing the concordances by 32% and 8%,
158 respectively. Finally, there was some additional attenuation in model 4 (vs model 3) when 12 more
159 covariates were included in the analyses (**Table 4**).

160
161 As a sensitivity analysis we included a fifth model with diminished sample sizes (owing to missing
162 covariate data, **Supplementary Table 1**) that additionally adjusted for cystatin-C, HbA1c, forced
163 expiratory volume, and HDL cholesterol. The inclusion of these variables (and the loss of 16.5% of the
164 sample owing to missing data) resulted in further attenuation of the DHA% vs. outcome relationships
165 (**Supplementary Tables 2-4**). Finally, secondary analyses using spline models did not significantly
166 improve upon the continuous models for any outcome and for any level of adjustment (data not shown).

167
168 As noted, there were monotonic inverse relations between DHA% and risk for testing positive and for
169 hospitalization. This was also true for death through the fourth quintile, but the trend reversed for the
170 highest quintile. Thus, it was of interest to explore the differences in risk factor and demographic
171 profiles across the quintiles of DHA% among the 235 individuals who died to see if some characteristic of
172 those in quintile 5 might help explain this reversal, especially vs quintile 4 (where the favorable trend
173 was still evident, **Supplementary Table 5**). The most obvious (and only statistically significant) difference
174 between quintiles 5 and 4 was in reported fish oil supplement use, with 22% of the former reporting use
175 and 61% of the latter ($p=0.002$). This naturally explains why this group had the highest DHA levels.
176 Quintile 5 subjects were also less likely to be white than quintile 4 subjects (74% vs 93%, $p=0.1$) and
177 exercised less, but also tended to be younger and less obese.

178 179 **Discussion**

180 The purpose of this study was to examine the relationships between plasma DHA% at baseline in the
181 UKBB and three COVID-19 related outcomes. We found that a 1-SD higher DHA% was associated with an
182 8% lower risk for testing positive for SARS-CoV-2 and an 11% lower risk for hospitalization in the
183 multivariable adjusted models. The relationship with risk for death with COVID-19 was also lower (5%
184 lower per 1-SD of DHA%), but it was not statistically significant. Thus, a higher n-3 level appeared to be
185 protective against both getting infected with the virus and with having a severe enough infection to
186 require hospitalization. Regarding risk for death with COVID-19, across the first four DHA% quintiles,
187 risk decreased in a strongly dose-related manner. However, in the highest DHA quintile, the trend
188 reversed, and the difference (from quintile 1) was no longer significant. Beyond the quintile 5
189 enrichment in subjects reporting fish oil supplement use and in non-white participants, the reasons for
190 this partial reversal are unclear; but caution should be used given the small number of deaths ($n=235$).
191 Finally, we were able translate DHA% quintiles into the more familiar Omega-3 Index, and we found that

192 the highest risk (i.e., quintile 1) eO3I value was around 3.5%, whereas the lowest risk (quintile 5) value
193 was around 8%. These values comport well with the O3I risk cut points [originally proposed in 2004 for
194 death from cardiovascular disease (7)] of <4% (high risk) and >8% (low risk) and imply that these target
195 levels apply to COVID-19 outcomes as well.

196
197 In general, our findings support the previous work of Julkunen et al. who reported on the relations
198 between risk for severe (i.e., hospitalization with) COVID-19 and multiple circulating biomarkers in the
199 UK Biobank(15). They found that a 1 SD increase in DHA% was associated with about a 23% reduction in
200 risk for hospitalization in an age- and sex-adjusted model (compared to 25% here in Model 2). They did
201 not adjust for any other covariates, however, nor did they report on either test positivity or mortality.
202 Sun et al.(16) also published on the relationships between multiple fatty acid metrics and COVID-19
203 outcomes in the UKBB. Our report also differs from theirs in several ways. First, we were able to
204 translate NMR plasma FA data to the eO3I, a metric that has been widely used clinically to risk stratify
205 patients for a variety of conditions(23-29). Second, although Sun et al. adjusted for more variables than
206 Julkunen et al. did, their list included only age, sex, ethnicity, BMI, Townsend deprivation index, and
207 assessment center. As noted, we adjusted for additional variables including those reported by Ho et
208 al.(21) to be significant determinants of risk for testing positive in hospital for SARS-CoV-2 and those
209 reflecting better dietary habits. Third, like Julkunen et al., Sun et al. did not examine risk for death.
210 Finally, uniquely compared to others, we have reported quintile level relationships and explored non-
211 linear relationships between DHA% and COVID-19 outcomes. The latter could help define optimal or
212 target blood O3I levels potentially useful in clinical practice.

213
214 Other reports from within the UKBB have described significant inverse relationships between reported
215 fish oil supplement use [which is associated with a higher O3I] and risk for death from all causes, risk for
216 incident cardiovascular events(30) as well as primary liver cancer(31), inflammatory bowel disease(32),
217 dementia(33), and as noted earlier, COVID-19(17).

218
219 Outside of the UKBB, the associations between the O3I or other blood n-3 biomarkers and a variety of
220 COVID-19 related outcomes in small studies (<100 patients each) were reported. We(8) and a research
221 group in Chile(9, 10) have both shown that higher O3I levels were associated with better clinical
222 outcomes. A study in 26 children with multi-system inflammatory syndrome linked to COVID-19
223 infection found lower levels of EPA and DHA compared with historical controls(34). Two double-blind,
224 randomized, controlled trials (RCTs) used n-3 PUFAs to treat COVID-19. Doaei et al. compared an
225 EPA+DHA enriched enteral nutrition product (n=28) with regular enteral nutrition (n=73) critically ill
226 patients hospitalized with COVID-19(13) and reported a higher 1-month survival rate, better renal
227 function, improved lymphocyte counts and better arterial blood gas parameters. Sedhigiyani et al.
228 compared hydroxychloroquine treatment to hydroxychloroquine plus n-3 FAs and found that patients
229 randomized to the latter regimen had less myalgias and fatigue, and lower erythrocyte sedimentation
230 rates and CRP levels(35).

231 **Mechanisms**

232 There are several mechanisms that could, in theory, explain the relationships observed here. Beginning
233 with the reduced risk for positive infection, the SARS-COV-2 virus is known to infect the host cells via
234 binding of the spike (S) glycoprotein with the surface ACE2 receptors, expressed in the pneumocytes and
235 other cell types. An *in silico* study by Vivar-Sierra et al. found that DHA and EPA also had the potential to
236 hold the S glycoprotein in a closed confirmation(36). These findings were confirmed by Goc et al.(37)
237 who studied the effect of EPA on host cellular proteases such as transmembrane protease serine
238 protease-2 (TMPRSS-2) and cathepsins that cleave spike proteins and enable cellular entry. EPA
239 effectively inhibited the enzymatic activity of cathepsin L and TMPRSS2. Finally, n-3 PUFAs may also play

240 a role in intracellular mechanisms of inhibiting viral replication. MERS-CoV is known to reprogram the
241 Sterol Regulatory Element Binding Protein (SREBP) dependent lipogenesis pathway to ensure its
242 replication(38). N-3 fatty acids are intracellular inhibitors of SREBP transcription and maturation and
243 may play role in counteracting the viral activation of SREBP1/2 thus decreasing viral replication.
244 N-3 fatty acids are known to have anti-inflammatory actions via alterations in membrane physio-
245 chemistry which alter the activity of toll-like receptor 4, diminishing signal transduction to nuclear factor
246 kappa B which in turn blunts the signaling cascade that produces inflammatory cytokines and adhesion
247 molecules(39). In addition, n-3 fatty acids serve as substrates for the production of a wide array of
248 oxylipins (prostaglandins, leukotrienes, and inflammation resolving mediators) that work in harmony not
249 only suppress inflammatory pathways, but also actively promote the resolution of inflammation (for
250 reviews see (2-4, 40, 41)). Taken together, there is a strong scientific rationale for a favorable effect of
251 higher tissue n-3 levels and protection against both infection with SARS-CoV-2 and its downstream
252 sequelae.

253 **Strengths and weakness**

254 The greatest strength of this study was the ability to query the UKBB data base with >110,000
255 individuals with baseline n-3 FA levels measured and then followed for >10 years. Second, we were able
256 to link blood n-3 levels with three important COVID-19 related outcomes: positive testing,
257 hospitalization and death. We also considered several more relevant covariates in our modeling than
258 past authors have included reducing the chances for – but by no means eliminating - unmeasured
259 confounding. HRs for each outcome were not materially affected by the inclusion of fruit, vegetable and
260 fiber intakes as covariates. This suggests that higher DHA levels are not simply a surrogate marker of a
261 healthier diet. Finally, we translated nuclear magnetic resonance -derived n-3 metrics into the more
262 familiar and clinically useful O3I metric.

263 As to limitations, the first is one common to of all studies linking circulating fatty acid levels measured at
264 baseline with disease outcomes occurring many years later: how stable are blood n-3 FA levels over
265 time? How confident can we be that levels measured at baseline were the same at the outbreak of the
266 pandemic. In the Framingham Offspring cohort, we found that within-persons, the RBC-based O3I was
267 stable between 1999 and 2006 in subjects who did not initiate fish oil supplementation; naturally it
268 increased in those who did(42). Other studies have examined plasma fatty acid stability over time and
269 reported pre-to-post correlations of between 0.5 and 0.8(43-46). Importantly, when baseline levels and
270 follow-up levels were each used to predict risk for incident heart failure in one study(46), both metrics
271 were equally predictive. In the UKBB cohort, baseline (2006-2010) fish oil supplement use was reported
272 by 31% and the consumption of at least 2 meals per week of oily fish by 18%(20). At a random repeat
273 visit between 2012-2013 in 20,334 subjects, supplement use was reported by 32.7%, and >1 oily fish
274 serving per week by 20%. Hence it is reasonable to assume that since the two major determinants of
275 blood n-3 levels remained stable, that baseline n-3 biomarker levels generally reflected levels later in
276 life. Indeed, any major shifts in DHA% after baseline would likely have biased our results towards the
277 null, suggesting that the relationships detected may in fact be stronger than they appear.

278 Another potential limitation is the impact of vaccination status on our findings. The study period
279 covered by this report was from January 1, 2020 (herein defined as the beginning of the pandemic) to
280 March 23, 2021. By the latter date, about 38% of the UK population had received at least one dose of
281 the vaccine, but only 2.6% had received two doses(47). Vaccination has been shown to not only reduce
282 the severity of COVID-19 once contracted, but also to lower the risk for testing positive(48).
283 Unfortunately, data on vaccination status were not available for this analysis, but in order for differential
284 vaccination status to have biased our results, one would have to posit that people with higher n-3 levels
285 were more likely to have been vaccinated than those with lower levels during the approximately 3-4
286 month period of this study for which vaccines were available (Dec 2020-March 2021). Although this is
287 plausible [i.e., higher n-3 levels are associated with higher SES and healthful behaviors and exercise and

288 a greater consumption of oily fish and fish oil supplements], we are unable to confirm or deny this
289 hypothesis.

290 Finally, by its very nature, the UKBB is not a random selection of all individuals in the UK; it is limited to
291 those in a fixed age range who agreed to participate. Thus, the results should not be generalized beyond
292 that context, and outcome data (all taken from electronic medical records) were not formally
293 adjudicated, potentially introducing some bias.

294 **Conclusion**

295 In this study we confirmed the findings of previous investigations that a low n-3 status was associated
296 with increased risk for hospitalization with COVID-19. We extended these findings by also showing
297 reduced risk for testing positive with the virus and by providing evidence that the risk for death may also
298 be reduced. Furthermore, we identified eO3I levels associated with the least (<4%) and greatest (>8%)
299 protection from COVID-19. Taken together, these results suggest that increased intakes of n-3 (from oily
300 fish and/or taking n-3 supplements) should be encouraged to raise the O3I and possibly reduce the risk
301 for COVID-19, and perhaps other, future pulmonary viral infections.

302

303 **Acknowledgements**

304 WSH designed the research; NLT conducted the research, analyzed the data and performed statistical
305 analysis; JW assisted in variable and dataset creation; WSH, NLT and SPS wrote the paper; WSH had
306 primary responsibility for the final content. All authors have read and approved the final manuscript.

307 **Data Sharing**

308 Codebook and analytic code related to data described in the manuscript will be made available upon
309 reasonable request pending application to and approval by the Fatty Acid Research Institute. Raw data
310 are available via standard application procedures directly from the UK Biobank.

311

References

1. Louca P, Murray B, Klaser K, Graham MS, Mazidi M, Leeming ER, et al. Modest effects of dietary supplements during the COVID-19 pandemic: insights from 445 850 users of the COVID-19 Symptom Study app. *BMJ Nutr Prev Health* 2021;4(1):149-57.
2. Panigrahy D, Gilligan MM, Huang S, Gartung A, Cortés-Puch I, Sime PJ, et al. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? *Cancer metastasis reviews* 2020;39(2):337-40.
3. Hathaway D, Pandav K, Patel M, Riva-Moscato A, Singh BM, Patel A, et al. Omega 3 Fatty Acids and COVID-19: A Comprehensive Review. *Infect Chemother* 2020;52(4):478-95.
4. Regidor PA, Santos FG, Rizo JM, Egea FM. Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19. *Medical hypotheses* 2020;145:110340.
5. Weill P, Plissonneau C, Legrand P, Rioux V, Thibault R. May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients? *Biochimie* 2020;179:275-80.
6. Chiang N, Serhan CN. Specialized pro-resolving mediator network: an update on production and actions. *Essays Biochem* 2020;64(3):443-62.
7. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? *Prev Med* 2004;39(1):212-20.
8. Asher A, Tintle NL, Myers M, Lockshon L, Bacareza H, Harris WS. Blood omega-3 fatty acids and death from COVID-19: A pilot study. *Prostaglandins, leukotrienes, and essential fatty acids* 2021;166:102250.
9. Ramírez-Santana M, Zapata Barra R, Ñunque González M, Müller JM, Vásquez JE, Ravera F, et al. Inverse Association between Omega-3 Index and Severity of COVID-19: A Case-Control Study. *International journal of environmental research and public health* 2022;19(11):6445.
10. Zapata B. R, Müller JM, Vásquez JE, Ravera F, Lago G, Cañón E, et al. Omega-3 Index and Clinical Outcomes of Severe COVID-19: Preliminary Results of a Cross-Sectional Study. *International journal of environmental research and public health* 2021;18(15):7722.
11. Suh W, Urits I, Viswanath O, Kaye AD, Patel H, Hall W, et al. Three Cases of COVID-19 Pneumonia That Responded to Icosapent Ethyl Supportive Treatment. *Am J Case Rep* 2020;21:e928422.
12. Berger AA, Sherburne R, Urits I, Patel H, Eskander J. Icosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infection. *Cureus* 2020;12(9):e10211.
13. Doaei S, Gholami S, Rastgoo S, Gholamalizadeh M, Bourbour F, Bagheri SE, et al. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial. *J Transl Med* 2021;19(1):128.
14. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine* 2015;12(3):e1001779.
15. Julkunen H, Cichońska A, Slagboom PE, Würtz P, Nightingale Health UKBI. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. *eLife* 2021;10:e63033.
16. Sun Y, Chatterjee R, Ronanki A, Ye K. Circulating Polyunsaturated Fatty Acids and COVID-19: A Prospective Cohort Study and Mendelian Randomization Analysis. *Front Med (Lausanne)* 2022;9:923746.
17. Ma Y, Zhang L, Zeng R, Luo D, Jiang R, Wu H, et al. Associations of habitual fish oil use with risk of SARS-CoV-2 infection and COVID-19-related outcomes in UK: national population based cohort study. *medRxiv* 2022:2022.09.14.22279933.
18. Collins R. What makes UK Biobank special? *Lancet* 2012;379(9822):1173-4.

19. Wurtz P, Raiko JR, Magnussen CG, Soininen P, Kangas AJ, Tynkkynen T, et al. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. *Eur Heart J* 2012;33(18):2307-16.
20. Schuchardt JP, Tintle N, Westra J, Harris WS. Estimation and predictors of the Omega-3 Index in the UK Biobank. *The British journal of nutrition* 2022;1-40.
21. Ho FK, Celis-Morales CA, Gray SR, Katikireddi SV, Niedzwiedz CL, Hastie C, et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. *BMJ open* 2020;10(11):e040402.
22. Bradbury KE, Young HJ, Guo W, Key TJ. Dietary assessment in UK Biobank: an evaluation of the performance of the touchscreen dietary questionnaire. *Journal of nutritional science* 2018;7:e6.
23. Block RC, Harris WS, Reid KJ, Sands SA, Spertus JA. EPA and DHA in Blood Cell Membranes from Acute Coronary Syndrome Patients and Controls. *Atherosclerosis* 2007;197:821-8.
24. Ammann EM, Pottala JV, Robinson JG, Espeland MA, Harris WS. Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS). *Prostaglandins, leukotrienes, and essential fatty acids* 2017;121:68-75.
25. Harris WS, Del Gobbo L, Tintle NL. The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies. *Atherosclerosis* 2017;262:51-4.
26. McBurney MI, Tintle NL, Vasan RS, Sala-Vila A, Harris WS. Using an erythrocyte fatty acid fingerprint to predict risk of all-cause mortality: the Framingham Offspring Cohort. *Am J Clin Nutr* 2021.
27. Dai XW, Zhang B, Wang P, Chen CG, Chen YM, Su YX. Erythrocyte membrane n-3 fatty acid levels and carotid atherosclerosis in Chinese men and women. *Atherosclerosis* 2014;232(1):79-85.
28. Filipovic MG, Aeschbacher S, Reiner MF, Stivala S, Gobbato S, Bonetti N, et al. Whole blood omega-3 fatty acid concentrations are inversely associated with blood pressure in young, healthy adults. *Journal of hypertension* 2018;36(7):1548-54.
29. Markhus MW, Skotheim S, Graff IE, Froyland L, Braarud HC, Stormark KM, et al. Low omega-3 index in pregnancy is a possible biological risk factor for postpartum depression. *PloS one* 2013;8(7):e67617.
30. Li Z-H, Zhong W-F, Liu S, Kraus VB, Zhang Y-J, Gao X, et al. Associations of habitual fish oil supplementation with cardiovascular outcomes and all cause mortality: evidence from a large population based cohort study. *BMJ (Clinical research ed)* 2020;368:m456.
31. Jiang W, Li FR, Yang HH, Chen GC, Hua YF. Relationship Between Fish Oil Use and Incidence of Primary Liver Cancer: Findings From a Population-Based Prospective Cohort Study. *Front Nutr* 2021;8:771984.
32. Huang X, Li Y, Zhuang P, Liu X, Zhang Y, Zhang P, et al. Habitual Fish Oil Supplementation and Risk of Incident Inflammatory Bowel Diseases: A Prospective Population-Based Study. *Front Nutr* 2022;9:905162.
33. Ma H, Zhou T, Li X, Heianza Y, Qi L. Use of fish oil supplements is differently related to incidence of all-cause and vascular dementia among people with the distinct APOE ϵ 4 dosage. *Clinical nutrition (Edinburgh, Scotland)* 2022;41(3):731-6.
34. Verduci E, Risé P, Di Profio E, Fiori L, Vizzuso S, Dilillo D, et al. Blood Fatty Acids Profile in MIS-C Children. *Metabolites* 2021;11(11).
35. Sedighiyan M, Abdollahi H, Karimi E, Badeli M, Erfanian R, Raeesi S, et al. Omega-3 polyunsaturated fatty acids supplementation improve clinical symptoms in patients with Covid-19: A randomised clinical trial. *International journal of clinical practice* 2021;75(12):e14854.

36. Vivar-Sierra A, Araiza-Macías MJ, Hernández-Contreras JP, Vergara-Castañeda A, Ramírez-Vélez G, Pinto-Almazán R, et al. In Silico Study of Polyunsaturated Fatty Acids as Potential SARS-CoV-2 Spike Protein Closed Conformation Stabilizers: Epidemiological and Computational Approaches. *Molecules* 2021;26(3).
37. Goc A, Niedzwiecki A, Rath M. Polyunsaturated ω -3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry. *Scientific reports* 2021;11(1):5207.
38. Yuan S, Chu H, Chan JF, Ye ZW, Wen L, Yan B, et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. *Nat Commun* 2019;10(1):120.
39. Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. *Biochemical Society transactions* 2017;45(5):1105-15.
40. Kothapalli KSD, Park HG, Brenna JT. Polyunsaturated fatty acid biosynthesis pathway and genetics. implications for interindividual variability in prothrombotic, inflammatory conditions such as COVID-19. *Prostaglandins, leukotrienes, and essential fatty acids* 2020;162:102183.
41. Arnardottir H, Pawelzik SC, Öhlund Wistbacka U, Artiach G, Hofmann R, Reinholdsson I, et al. Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial. *Frontiers in physiology* 2020;11:624657.
42. Harris WS, Pottala JV, Vasan RS, Larson MG, Robins SJ. Changes in erythrocyte membrane trans and marine fatty acids between 1999 and 2006 in older Americans. *The Journal of nutrition* 2012;142(7):1297-303.
43. Lai HT, de Oliveira Otto MC, Lemaitre RN, McKnight B, Song X, King IB, et al. Serial circulating omega 3 polyunsaturated fatty acids and healthy ageing among older adults in the Cardiovascular Health Study: prospective cohort study. *BMJ (Clinical research ed)* 2018;363:363:k4067.
44. Ma J, Folsom AR, Eckfeldt JH, Lewis L, Chambless LE. Short- and long-term repeatability of fatty acid composition of human plasma phospholipids and cholesterol esters. *Am J Clin Nutr* 1995;62:572-8.
45. Zheng JS, Imamura F, Sharp SJ, Koulman A, Griffin JL, Mulligan AA, et al. Changes in plasma phospholipid fatty acid profiles over 13 years and correlates of change: European Prospective Investigation into Cancer and Nutrition-Norfolk Study. *Am J Clin Nutr* 2019;109(6):1527-34.
46. Djousse L, Petrone AB, Weir NL, Hanson NQ, Glynn RJ, Tsai MY, et al. Repeated versus single measurement of plasma omega-3 fatty acids and risk of heart failure. *European journal of nutrition* 2014;53(6):1403-8.
47. Richie H, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, et al. Causes of death. <https://ourworldindata.org/covid-vaccinations?country=GBR#citation>, (accessed August 20, 2022).
48. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. *Int J Infect Dis* 2022;114:252-60.

Table 1. Distribution of analysis variables¹

	All	Ever tested for COVID
N	110,584	26,597
Sex - Male	49,638 (44.9%)	12,368 (46.5%)
Race - White	104,340 (94.4%)	25,038 (94.1%)
Positive tests ²	4081 (3.7%)	4081 (15.3%)
Hospitalized with COVID ²	837 (0.8%)	837 (3.1%)
Dead with COVID ²	235 (0.2%)	235 (0.9%)
Age (on January 1, 2020)	68.1 (8.1)	68.6 (8.2)
Years since enrollment	11.39 (0.88)	11.39 (0.89)
Estimated ³ Omega-3 Index (%)	5.6 (1.89)	5.56 (1.91)
Plasma DHA (% of total fatty acids)	2.02 (0.68)	2 (0.68)
Waist Circumference (cm)	90 (13.29)	91.23 (13.74)
BMI (kg/m ²)	27.38 (4.73)	27.77 (4.93)
Townsend Deprivation Index ⁴	-1.35 (3.07)	-1.17 (3.19)
Education - College/University	42,106 (38.1%)	9,657 (36.3%)
Smoking status - Never	61,236 (55.4%)	13,822 (52%)
Self-report health - Excellent	18,606 (16.8%)	3,946 (14.8%)
Long standing illness - None	74,205 (67.1%)	16,325 (61.4%)
Blood pressure medications - Yes	4844 (4.4%)	1398 (5.3%)
Diabetes - Yes	5339 (4.8%)	1629 (6.1%)
Walking pace – Slow ⁵	7943 (7.2%)	2483 (9.3%)
Fresh fruit (pieces per day)	2.23 (1.58)	2.23 (1.65)
Dried fruit (pieces per day)	1.89 (2.29)	1.88 (2.37)
Fresh Vegetables/Salad (heaped tbsp per day)	2.16 (2.17)	2.14 (2.15)
Cooked Vegetables (heaped tbsp per day)	1.9 (2.51)	1.91 (2.52)
Grain fiber (estimated g/week)	21.76 (14.52)	21.34 (14.32)

1. N (percent) or mean (SD)
2. Between January 1, 2020 and March 23, 2021
3. Based on Schuchardt et al.(20)
4. An index of 0 means ‘average deprivation’ in the UK; a negative value means less deprived than average and a positive value means more deprived than average.
5. <3 miles per hr (“steady” is 3-4 and “fast” is >4)

Table 2. Hazard ratios (HRs, 95% CI) from Cox-proportional hazards models by quintile for testing positive for SARS-CoV-2 as a function of plasma DHA% among those who were ever tested (n=26,597)

Plasma DHA% Quintile (Q; min, max)	Unadjusted	Model 2 ¹	Model 3 ¹	Model 4 ¹
Q1 (<1.49; reference)	1	1	1	1
Q2 (1.49, 1.79)	0.94 (0.86,1.03)	0.96 (0.88,1.05)	0.99 (0.9,1.08)	0.99 (0.91,1.09)
Q3 (1.80, 2.09)	0.86 (0.78,0.94)**	0.90 (0.82,0.99)*	0.95 (0.86,1.04)	0.97 (0.89,1.07)
Q4 (2.10, 2.50)	0.73 (0.66,0.8)***	0.79 (0.72,0.87)***	0.85 (0.76,0.93)**	0.89 (0.80,0.98)*
Q5 (>2.50)	0.60 (0.55,0.67)***	0.68 (0.61,0.76)***	0.74 (0.67,0.82)***	0.79 (0.71,0.89)***
Linear across quintiles	0.89 (0.87,0.9)***	0.91 (0.89,0.93)***	0.94 (0.91,0.96)***	0.95 (0.92,0.97)***
Linear trend per SD	0.84 (0.81,0.86)***	0.87 (0.84,0.9)***	0.90 (0.87,0.93)***	0.92 (0.89,0.96)***

¹Model 2: adjusted for age at start of pandemic, sex, and race; Model 3: Model 2 covariates + waist circumference; Model 4: Model 3 covariates + Townsend Deprivation Index, time since enrollment, smoking status, education, Self-reported health, blood pressure medications, slow walking pace, fresh fruit, dried fruit, fresh vegetables, cooked vegetables and grain fiber. * p<0.05; ** p<0.01; *** p<0.001.

Table 3. Hazard ratios (HRs, 95% CI) from Cox-proportional hazards models for hospitalization with COVID-19 as a function of plasma DHA% (n=110,584)

Plasma DHA% Quintile (Q; min, max)	Unadjusted	Model 2 ¹	Model 3 ¹	Model 4 ¹
Q1 (<1.49; reference)	1	1	1	1
Q2 (1.49, 1.79)	0.92 (0.76,1.11)	0.95 (0.79,1.15)	1.07 (0.88,1.29)	1.11 (0.92,1.34)
Q3 (1.80, 2.09)	0.72 (0.59,0.88)**	0.74 (0.61,0.91)**	0.90 (0.74,1.11)	0.97 (0.79,1.19)
Q4 (2.10, 2.50)	0.56 (0.45,0.69)***	0.56 (0.45,0.7)***	0.73 (0.59,0.92)**	0.81 (0.65,1.02)
Q5 (>2.50)	0.48 (0.38,0.6)***	0.46 (0.36,0.58)***	0.63 (0.5,0.8)***	0.74 (0.58,0.94)*
linear-trend-quintiles	0.82 (0.78,0.86)***	0.82 (0.78,0.86)***	0.89 (0.84,0.93)***	0.92 (0.87,0.97)**
linear-trend-per SD	0.75 (0.7,0.81)***	0.75 (0.69,0.81)***	0.84 (0.78,0.91)***	0.89 (0.83,0.97)**

Model 2: adjusted for age at start of pandemic, sex, and race; Model 3: Model 2 covariates + waist circumference; Model 4: Model 3 covariates + Townsend Deprivation Index, time since enrollment, smoking status, education, Self-reported health, blood pressure, slow walking pace, fresh fruit, dried fruit, fresh vegetables, cooked vegetables and grain fiber. * p<0.05; ** p<0.01; *** p<0.001

Table 4. Hazard ratios (HRs, 95% CI) from Cox-proportional hazards models for death with COVID-19 as a function of plasma DHA% (n=110,584)

Plasma DHA% Quintile (Q; min, max)	Unadjusted	Model 2 ¹	Model 3 ¹	Model 4 ¹
Q1 (<1.49; reference)	1	1	1	1
Q2 (1.49, 1.79)	0.84 (0.59,1.21)	0.86 (0.6,1.24)	0.97 (0.67,1.39)	1.03 (0.71,1.48)
Q3 (1.80, 2.09)	0.69 (0.47,1.01)	0.69 (0.47,1.01)	0.84 (0.57,1.24)	0.93 (0.63,1.38)
Q4 (2.10, 2.50)	0.42 (0.27,0.66)***	0.40 (0.25,0.63)***	0.53 (0.33,0.83)**	0.61 (0.39,0.98)*
Q5 (>2.50)	0.72 (0.49,1.05)	0.61 (0.41,0.9)*	0.85 (0.57,1.27)	1.04 (0.69,1.57)
linear-trend-quintiles	0.87 (0.8,0.96)**	0.84 (0.77,0.92)***	0.92 (0.83,1.01)	0.96 (0.87,1.06)
linear-trend-per SD	0.83 (0.72,0.95)**	0.78 (0.68,0.9)***	0.88 (0.77,1.01)	0.95 (0.83,1.09)

¹Model 2: adjusted for age at start of pandemic, sex, and race; Model 3: Model 2 covariates + waist circumference; Model 4: Model 3 covariates + Townsend Deprivation Index, time since enrollment, smoking status, education, Self-reported health, blood pressure, slow walking pace, fresh fruit, dried fruit, fresh vegetables, cooked vegetables and grain fiber. * p<0.05; ** p<0.01; *** p<0.001

Table 5. Effects of the removal of age, sex, race and waist circumference from model 3 on model concordance for the COVID-19 outcomes of interest.

	Concordance	Absolute Decrease				Percent Decrease*			
		Age	Sex	Waist circumference	Race	Age	Sex	Waist circumference	Race
Positive test	0.6298	0.0584	0.0001	0.0038	0.0042	45.0%	0.0%	3.0%	3.0%
Hospitalization	0.7047	0.0213	0.0011	0.0379	0.0121	10.0%	1.0%	19.0%	6.0%
Death	0.8088	0.0998	0.0011	0.024	0.0181	32.0%	0.0%	8.0%	6.0%

* Calculated by dividing the absolute decrease by the concordance - 0.5

Figure Legend

Figure 1. The percent of individuals experiencing COVID-19 outcomes between January 1, 2020 and March 23, 2021 by quintile of the plasma DHA%. The median estimated Omega-3 Index of each quintile is also shown. A, testing positive for SARS-CoV-2 (n=26,597); B, being hospitalized with COVID-19 (n=110,584); and C, dying with COVID-19 (n=110,584).

